Escadep
(Escitalopram)

ایسکاڈیپ
(ایسٹالوپرام)

10 mg Tablets

۱۰ ملی گرام گولیاں

DESCRIPTION
Escadep tablet (Escitalopram) is a potent selective serotonin reuptake inhibitor (SSRI). It is the active isomer of citalopram.

COMPOSITION
Each film coated tablet contains:
Escitalopram as oxalate (Platinum Specs.) .....10 mg.
Product Complies Platinum Specs.

DOSAGE
In Adults: The initial dose of Escadep tablets is 10 mg once daily. If required, the dose might be increased to 20 mg after a minimum of one week period.

In Old Age: Single oral dose of 10 mg/day is recommended.

In Hepatic Dysfunction: Not more than 10 mg/day.

In Renal Dysfunction: No dosage adjustment is required in mild to moderate renal impairment. It should be cautiously given in severe renal dysfunction.

INDICATIONS
Treatment of major depressive disorder.
Prevention of depression relapse.

CONTRAINDICATIONS
Escadep tablet is contraindicated in patients with known hypersensitivity to Escitalopram oxalate, citalopram or any ingredient of the product.

SIDE EFFECTS
The side effects reported are agitation, restlessness, blurred vision, diarrhea, difficulty in sleeping, drowsiness, dry mouth, fever, frequent urination, headache, indigestion, nausea, increased or decreased appetite, increased sweating, sexual difficulties like decreased sexual ability or libido & ejaculatory delay, change in taste, tremor, and weight changes. Rarely confusion, dizziness, lightheadedness, skin rash, itching, suicidal thoughts, and vomiting have occurred.

PRECAUTIONS
Use with Monoamine Oxidase Inhibitors (MAOIs) Like with other SSRIs, combination with monoamine oxidase inhibitor (MAOI) might result in serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability, rapid changes in vital signs, and mental status changes, including extreme agitation progressing to delirium and coma. The patients who switch from an SSRI to an MAOI might present with the same features. Hence Escadep tablets should not be coadministered with an MAOI or within 2 weeks of discontinuing treatment with an MAOI. Also, at least a gap of 2 weeks should be given after discontinuing Escadep tablets and starting an MAOI.

Chances of Mania or Hypomania: Mania/hypomania might occur in patients treated with Escadep tablets. In such cases Escadep tablets should be discontinued Also, Escadep tablets should be used with caution in patients with history of mania.

Use In Patients with History of Seizures: Like other antidepressants, Escadep tablets should be cautiously used in patients with a history of seizure disorder.

Use during Pregnancy: The safety of Escadep tablets during pregnancy has not been established. Therefore, Escadep tablets should not be used during pregnancy, unless the expected benefits to the patient markedly outweigh the possible hazards to the fetus.

Use in Nursing Mothers: The safety of Escadep tablets during breastfeeding has not been established. Since Escitalopram is excreted in human milk. Escadep tablets should not be administered to nursing mothers unless the expected benefits to the patient markedly outweigh the possible hazards to the child.
Use in Children: Safety and efficacy in children under the age of 18 years have not been established.

Use in Old Age: Though no overall differences in safety or efficacy between old age patients and younger patients was observed, dose of 10 mg is the recommended dosage for elderly patients.

DRUG DEPENDENCE
Escadep tablets is not a controlled substance. The psychological and physical dependence, and hence abuse liability, of Escadep tablets have been found to be low.

OVERDOSE
Use of Escitalopram in high doses of up to 600 mg has been found to be associated with reversible symptoms like dizziness, sweating, nausea, vomiting, tremor, and somnolence. Rarely confusion, loss of consciousness, convulsions, coma, sinus tachycardia, cyanosis, hyperventilation and rhabdomyolysis might occur.
In such cases following measures should be taken: airway maintenance, gastric lavage, use of activated charcoal, cardiac and vital sign monitoring and general symptomatic and supportive measures. There is no specific antidote for Escitalopram.

DRUG INTERACTIONS
Because of reported drug interactions, special caution should be exercised while co-administering Escadep tablets with monoamine oxidase inhibitors (MAOIs), CNS drugs, alcohol, cimetidine, ketoconazole, desipramine and metoprolol.

STORAGE
Store below 30°C in a dry place, protect from light.
To be dispensed on the prescription of a registered medical practitioner only.
Keep out of the reach of children

PRESENTATION
Escadep tablets 10 mg: Pack of 10 tablets.

ہدایات :

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
دوا کو ۳۰ ڈگری سینٹی گریڈ سے کم درجہ حرارت پر خشک جگہ پر رکھیں،
روشنی سے بچائیں۔ صرف رجسٹرڈ ڈاکٹر کے نسخے پر فروخت کریں۔
بچوں کی پہنچ سے دُور رکھیں۔

Manufactured by:
Platinum
Pharmaceuticals (Pvt) Ltd.
A-20, North Western Industrial Zone,
Bin Qasim, Karachi-75020, Pakistan.

QAR No. AW12-0500

D1D

PGL-1402(409)

Platinum
Pharmaceuticals (Pvt.) Ltd.

Product : Escadep Tablet
Components: Leaflet (TP)
Country : local (pakistan)

Dimension: 85 mm x 145mm
Modified Date : 10-08-2012
Concepts by : Farooq Sami
Design by : Rahil Rahim
QAR No. AW12-0500
Supersedes : 060033-0405

COLORS
Black

Department	Marketing	Regulatory	Qulity Control	Quality Control Head	Procurement
Remarks					
Signature					
Date / Time					